BRCA1 and ovarian carcinoma: A previous study has shown that inhibiting USP1 can reduce the viability of BRCA1/2 mutant cancer cells (e.g. ovarian cancer cells), thereby USP1 is a SL partner of BRCA1 and has been a promising drug target in clinical cancer therapy (Simoneau et al. 2023).